Drug development has moved along way forward from the days of with
doctors peddling cauldrons of herbs and spices, however, the process can still miss
opportunities for full exploitation of a drug’s potential. Drug reprofiling provides a
chance for an established or a forgotten drug to move into a new area of therapy,
whether related to the known effects or in a completely new area. In an era of
environmental awareness and spiraling costs for traditional drug development, a
strategy to squeeze every benefit out of drugs with known safety, tolerability and
pharmacological parameters must be a strategically sound desire. We explore
examples of success in reprofiling, draw comparisons between techniques, and
finally provide two examples from the Valirx plc development pipeline currently
undergoing the process.
Keywords: Reprofiling, development, techniques, health economics, risperidone, cancer.
open access plus
Rights & PermissionsPrintExport